Blood Pressure Management Strategy After Clot Removal in Acute Ischemic Stroke
Compares blood pressure care based on collateral blood flow with standard care in stroke patients.
Plain-language title generated from the registry record
Registry title: Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke caused by a blocked large brain artery, whose artery was reopened by a procedure and whose blood pressure is high afterwards.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke from a blocked large artery at the front of the brain (internal carotid artery or M1/M2 segment of the middle cerebral artery). Baseline ASPECTS score at least 3 and NIHSS score at least 6.
- Earlier treatment
- Must have had endovascular treatment (EVT, a procedure to remove the clot), alone or with clot-dissolving drugs, within 24 hours of symptom onset. The artery must have reopened successfully (eTICI grade 2b50 or better).
- Biomarker or test result
- Two blood pressure readings (systolic) of 150 mmHg or higher within 3 hours after the artery reopened, at least 5 minutes apart. Randomization must be possible within 3 hours.
Main reasons for not taking part
- Disability before the stroke (mRS score above 1) or coma (GCS score below 8)
- Bleeding in the brain with symptoms before randomization
- Recent heart attack, serious heart failure or heart rhythm problems
- Severe kidney or liver disease, or dialysis
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07527013
- Record updated
- 22 April 2026
- Original description
The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale [mRS] score 0-2).Read full original descriptionShow less
Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)
The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale [mRS] score 0-2).
The study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program.
The primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.
Inclusion: Age ≥ 18 years；; Clinical diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (internal carotid artery or M1/M2 segment of the middle cerebral artery)；; Received EVT (including direct EVT and bridging therapy) within 24 hours of symptom onset；; Baseline ASPECTS score ≥ 3；; Baseline NIHSS score ≥ 6；; Successful recanalization achieved post-procedure (defined as expanded Thrombolysis in Cerebral Infarction [eTICI] grade ≥ 2b50); Two consecutive systolic blood pressure (SBP) measurements ≥ 150 mmHg within 3 hours post-recanalization (with a measurement interval of no less than 5 minutes)；; Able to complete randomization within 3 hours post-recanalization；; Informed consent signed by the patient or their legal representative.
Exclusion: Pre-stroke mRS score > 1；; Symptomatic intracerebral hemorrhage occurred before randomization; Comorbidities with a life expectancy < 6 months (e.g., malignant tumors); Any clinical condition judged by the research team that might limit compliance with study procedures; Within the past 3 months, occurrence of acute ST-segment elevation myocardial infarction (MI), acute decompensated heart failure, QTc > 500 ms, hospitalization or involuntary coronary intervention due to acute coronary syndrome, MI, or cardiac arrest; or heart failure (New York Heart Association [NYHA] class III/IV or left ventricular ejection fraction < 35%); or known history of ventricular tachycardia; History of severe renal insufficiency, acute renal failure, dialysis, or estimated glomerular filtration rate (eGFR) < 20 ml/min/1.72m²; History of severe hepatic disease, or Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) and/or Gamma-Glutamyl Transferase (GGT) ≥ 3×ULN and/or Total Bilirubin (TBIL) ≥ 2×ULN; Comatose state (Glasgow Coma Scale [GCS] score < 8); Aortic dissection, cervical artery dissection, or cerebral artery dissection; unruptured aortic aneurysm or cerebral aneurysm; or known arteriovenous malformation; Pregnant or lactating women; Participation in another clinical trial within the past 30 days.